On 8 March 2018, the Dutch Competition Authority, Autoriteit Consument & Markt (ACM), published a working paper on how competition law may be applied to abuses of dominance involving patented pharmaceuticals. The report argues that the so-called “pay-for-delay” cases in both the US and the EU are only the first step in exploring the application of competition law to such pharmaceutical products. In its enforcement strategy, the ACM indicated that the pharmaceutical industry will be a key area of interest to the ACM in the coming two years. The ACM will concentrate on the prices of medicines and competition in the pharmaceutical sector. Moreover, it will focus specifically on innovation incentives in the sector contributing to the development of new medicines, since it considers innovation and the affordability of medicines to be key factors for “healthy” competition.